XIGDUO XR 10/1000 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xigduo xr 10/1000 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack

astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg) - tablet, modified release - excipient ingredients: crospovidone; lactose; hypromellose; magnesium stearate; carmellose sodium; silicon dioxide; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).

XIGDUO XR 10/500 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 500 mg modified release tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xigduo xr 10/500 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 500 mg modified release tablets blister pack

astrazeneca pty ltd - metformin hydrochloride, quantity: 500 mg; dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg) - tablet, modified release - excipient ingredients: microcrystalline cellulose; lactose; silicon dioxide; hypromellose; crospovidone; carmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).

XIGDUO XR 5/1000 dapagliflozin 5 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xigduo xr 5/1000 dapagliflozin 5 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack

astrazeneca pty ltd - dapagliflozin propanediol monohydrate, quantity: 6.15 mg (equivalent: dapagliflozin, qty 5 mg); metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: carmellose sodium; lactose; hypromellose; silicon dioxide; crospovidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).

Xigduo 5mg1000mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

xigduo 5mg1000mg tablets

astrazeneca uk ltd - dapagliflozin propanediol monohydrate; metformin hydrochloride - tablet - 5mg ; 1gram

Xigduo 5mg850mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

xigduo 5mg850mg tablets

astrazeneca uk ltd - metformin hydrochloride; dapagliflozin propanediol monohydrate - tablet - 850mg ; 5mg

Ebymect European Union - English - EMA (European Medicines Agency)

ebymect

astrazeneca ab - dapagliflozin propanediol monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - type 2 diabetes mellitusfor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.for study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.type 1 diabetes mellitusedistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with bmi ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Xigduo European Union - English - EMA (European Medicines Agency)

xigduo

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - xigduo is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:•    in patients insufficiently controlled on their maximally tolerated dose of metformin alone •    in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products•    in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.for study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

QTERN 5/10 saxagliptin (as hydrochloride) / dapagliflozin (as propanediol monohydrate) 5 mg / 10 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

qtern 5/10 saxagliptin (as hydrochloride) / dapagliflozin (as propanediol monohydrate) 5 mg / 10 mg film-coated tablet blister pack

astrazeneca pty ltd - dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg); saxagliptin, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose; croscarmellose sodium; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid - qtern 5/10 is indicated as an adjunct to diet and exercise, in combination with metformin, to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and dapagliflozin is appropriate.

XIGDUO TABLET Canada - English - Health Canada

xigduo tablet

astrazeneca canada inc - dapagliflozin (dapagliflozin propanediol monohydrate); metformin hydrochloride - tablet - 5mg; 850mg - dapagliflozin (dapagliflozin propanediol monohydrate) 5mg; metformin hydrochloride 850mg - biguanides

XIGDUO TABLET Canada - English - Health Canada

xigduo tablet

astrazeneca canada inc - dapagliflozin (dapagliflozin propanediol monohydrate); metformin hydrochloride - tablet - 5mg; 1000mg - dapagliflozin (dapagliflozin propanediol monohydrate) 5mg; metformin hydrochloride 1000mg - biguanides